TrialVaccine2022

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.

María Eugenia-Toledo-Romaní et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.